
Nuvectis Pharma, Inc. – NASDAQ:NVCT
Nuvectis Pharma stock price today
Nuvectis Pharma stock price monthly change
Nuvectis Pharma stock price quarterly change
Nuvectis Pharma stock price yearly change
Nuvectis Pharma key metrics
Market Cap | 88.72M |
Enterprise value | N/A |
P/E | -9.45 |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | N/A |
Price/Book | 12.53 |
PEG ratio | 0.24 |
EPS | -1.38 |
Revenue | N/A |
EBITDA | -23.19M |
Income | -22.38M |
Revenue Q/Q | -100% |
Revenue Y/Y | -196.49% |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeNuvectis Pharma stock price history
Nuvectis Pharma stock forecast
Nuvectis Pharma financial statements
Jun 2023 | 0 | -5.70M | |
---|---|---|---|
Sep 2023 | 0 | -5.88M | |
Dec 2023 | -4.10M | -6.62M | 161.47% |
Mar 2024 | 0 | -4.17M |
2025 | 23.06M | -29.10M | -126.18% |
---|---|---|---|
2026 | 1.97M | -33.51M | -1700.81% |
2027 | 31.45M | -6.94M | -22.09% |
2028 | 75.11M | 12.28M | 16.36% |
Analysts Price target
Financials & Ratios estimates
2024-03-05 | -0.4 | -0.41 |
---|---|---|
2024-05-07 | -0.4 | -0.25 |
Jun 2023 | 24941000 | 4.60M | 18.48% |
---|---|---|---|
Sep 2023 | 22262000 | 5.57M | 25.05% |
Dec 2023 | 19185000 | 6.98M | 36.4% |
Mar 2024 | 19714000 | 5.69M | 28.87% |
Jun 2023 | -4.08M | 0 | 13.21M |
---|---|---|---|
Sep 2023 | -3.24M | 0 | 703K |
Dec 2023 | -3.85M | 0 | 917K |
Mar 2024 | -4.35M | 0 | 4.69M |
Nuvectis Pharma alternative data
Aug 2023 | 11 |
---|---|
Sep 2023 | 11 |
Oct 2023 | 11 |
Nov 2023 | 11 |
Dec 2023 | 11 |
Jan 2024 | 11 |
Feb 2024 | 11 |
Mar 2024 | 13 |
Apr 2024 | 13 |
May 2024 | 13 |
Jun 2024 | 13 |
Jul 2024 | 13 |
Nuvectis Pharma other data
Period | Buy | Sel |
---|---|---|
May 2024 | 5553 | 0 |
Nov 2024 | 22000 | 2755 |
Dec 2024 | 34000 | 0 |
-
What's the price of Nuvectis Pharma stock today?
One share of Nuvectis Pharma stock can currently be purchased for approximately $6.14.
-
When is Nuvectis Pharma's next earnings date?
Unfortunately, Nuvectis Pharma's (NVCT) next earnings date is currently unknown.
-
Does Nuvectis Pharma pay dividends?
No, Nuvectis Pharma does not pay dividends.
-
How much money does Nuvectis Pharma make?
Nuvectis Pharma has a market capitalization of 88.72M. Nuvectis Pharma made a loss 22.26M US dollars in net income (profit) last year or -$0.25 on an earnings per share basis.
-
What is Nuvectis Pharma's stock symbol?
Nuvectis Pharma, Inc. is traded on the NASDAQ under the ticker symbol "NVCT".
-
What is Nuvectis Pharma's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Nuvectis Pharma?
Shares of Nuvectis Pharma can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does Nuvectis Pharma have?
As Jul 2024, Nuvectis Pharma employs 13 workers.
-
When Nuvectis Pharma went public?
Nuvectis Pharma, Inc. is publicly traded company for more then 3 years since IPO on 4 Feb 2022.
-
What is Nuvectis Pharma's official website?
The official website for Nuvectis Pharma is nuvectis.com.
-
Where are Nuvectis Pharma's headquarters?
Nuvectis Pharma is headquartered at 1 Bridge Plaza, Fort Lee, NJ.
-
How can i contact Nuvectis Pharma?
Nuvectis Pharma's mailing address is 1 Bridge Plaza, Fort Lee, NJ and company can be reached via phone at +20 16143150.
Nuvectis Pharma company profile:

Nuvectis Pharma, Inc.
nuvectis.comNASDAQ
13
Biotechnology
Healthcare
Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src and YES1 kinases. The company was incorporated in 2020 and is based in Fort Lee, New Jersey.
Fort Lee, NJ 07024
CIK: 0001875558
ISIN: US67080T1088
CUSIP: 67080T108